Vanguard Group Inc. Has $324.08 Million Stake in Haemonetics Corporation $HAE

Vanguard Group Inc. lowered its stake in Haemonetics Corporation (NYSE:HAE) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,099,621 shares of the medical instruments supplier’s stock after selling 79,767 shares during the quarter. Vanguard Group Inc. owned approximately 10.15% of Haemonetics worth $324,081,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. TD Waterhouse Canada Inc. bought a new position in shares of Haemonetics in the fourth quarter worth about $25,000. University of Texas Texas AM Investment Management Co. bought a new position in Haemonetics in the 1st quarter valued at approximately $65,000. KBC Group NV raised its holdings in Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after buying an additional 401 shares during the last quarter. Vise Technologies Inc. boosted its position in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock worth $221,000 after buying an additional 225 shares during the period. Finally, CWC Advisors LLC. boosted its position in Haemonetics by 7.4% during the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier’s stock worth $241,000 after buying an additional 212 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 2.9%

Shares of NYSE HAE opened at $53.85 on Monday. The company has a market capitalization of $2.59 billion, a P/E ratio of 16.47, a price-to-earnings-growth ratio of 0.99 and a beta of 0.40. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The company’s 50 day moving average price is $71.19 and its 200-day moving average price is $66.77.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same quarter in the previous year, the company earned $1.02 EPS. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. Equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on HAE. JMP Securities reiterated a “market outperform” rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Needham & Company LLC cut their target price on shares of Haemonetics from $84.00 to $68.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Barrington Research cut their target price on shares of Haemonetics from $95.00 to $86.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Mizuho cut their target price on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.